IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Acquired by Fiera Capital Corp

Fiera Capital Corp grew its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 12.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 141,198 shares of the company's stock after purchasing an additional 15,463 shares during the period. Fiera Capital Corp owned approximately 0.17% of IDEXX Laboratories worth $58,377,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Angeles Wealth Management LLC raised its stake in IDEXX Laboratories by 2.4% in the third quarter. Angeles Wealth Management LLC now owns 1,078 shares of the company's stock valued at $545,000 after buying an additional 25 shares in the last quarter. Cranbrook Wealth Management LLC raised its stake in IDEXX Laboratories by 7.0% in the fourth quarter. Cranbrook Wealth Management LLC now owns 382 shares of the company's stock valued at $158,000 after buying an additional 25 shares in the last quarter. Perigon Wealth Management LLC raised its stake in IDEXX Laboratories by 1.8% in the fourth quarter. Perigon Wealth Management LLC now owns 1,474 shares of the company's stock valued at $632,000 after buying an additional 26 shares in the last quarter. Summit Trail Advisors LLC grew its holdings in shares of IDEXX Laboratories by 3.3% during the fourth quarter. Summit Trail Advisors LLC now owns 810 shares of the company's stock worth $335,000 after purchasing an additional 26 shares during the last quarter. Finally, First Horizon Advisors Inc. grew its holdings in shares of IDEXX Laboratories by 4.0% during the third quarter. First Horizon Advisors Inc. now owns 704 shares of the company's stock worth $356,000 after purchasing an additional 27 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

IDEXX Laboratories Stock Performance

NASDAQ:IDXX traded down $15.23 during mid-day trading on Friday, reaching $444.53. The stock had a trading volume of 553,751 shares, compared to its average volume of 753,210. The business has a 50 day simple moving average of $430.95 and a 200 day simple moving average of $452.96. IDEXX Laboratories, Inc. has a twelve month low of $398.50 and a twelve month high of $583.39. The company has a debt-to-equity ratio of 0.28, a quick ratio of 1.03 and a current ratio of 1.31. The firm has a market capitalization of $36.40 billion, a price-to-earnings ratio of 41.66, a PEG ratio of 3.47 and a beta of 1.37.

Insider Activity

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 344 shares of IDEXX Laboratories stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total value of $144,631.36. Following the completion of the sale, the director now directly owns 905 shares of the company's stock, valued at approximately $380,498.20. The trade was a 27.54 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director M Anne Szostak sold 3,000 shares of the business's stock in a transaction on Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the sale, the director now directly owns 3,061 shares of the company's stock, valued at $1,426,242.34. This represents a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 13,330 shares of company stock worth $6,161,276. Company insiders own 2.11% of the company's stock.

Analyst Ratings Changes

Several equities analysts have issued reports on IDXX shares. Piper Sandler raised their price objective on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a report on Monday, February 10th. Barclays raised their price objective on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a report on Tuesday, February 4th. Leerink Partners started coverage on IDEXX Laboratories in a report on Monday, December 2nd. They set an "outperform" rating and a $500.00 price target on the stock. StockNews.com lowered IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Wednesday, February 5th. Finally, Morgan Stanley lowered their price target on IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating on the stock in a report on Wednesday, January 29th. Four analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $533.75.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.